Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides Angiotensin and Neprilysin

  • End date
    May 23, 2022
  • participants needed
  • sponsor
    Oslo University Hospital
Updated on 23 January 2021
ejection fraction
chronic heart failure


The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.

Condition systolic heart failure
Treatment Sacubitril / Valsartan Oral Tablet
Clinical Study IdentifierNCT03553303
SponsorOslo University Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Patients must give written informed consent before any study assessment is performed
Ambulatory 18 years of age, male or female, treated at Ringerike Hospital
Patients with symptomatic chronic heart failure and reduced ejection fraction ( 40%)
Patients on optimized medical treatment for heart failure. -

Exclusion Criteria

Patients not able to comply in the study
Patients having contraindication for treatment with Entresto
Hypersensitivity to the active substances or to any of the excipients listed in section
Hyperkalemia: > 5.4 mmol/L
Known history of angioedema related to previous ACE inhibitor or ARB therapy
Hereditary or idiopathic angioedema
Concomitant use with Aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73m2)
End-stage renal disease (<15 mL/min per 1.73m2 or treatment by dialysis)
Severe hepatic impairment, biliary cirrhosis and cholestasis (Child-Pugh C classification)
Pregnancy Breast-feeding-
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note